down arrow

Jiangsu Nanfang Medical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100002WH0
  • SHG: 603880
CNY
9.12
-0.18 (-1.94%)

Sep 24

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Jiangsu Nanfang Medical Co., Ltd.

Why is Jiangsu Nanfang Medical Co., Ltd. ?

1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 3.73%
  • Poor long term growth as Net Sales has grown by an annual rate of -12.05% and Operating profit at -191.83% over the last 5 years
  • The company is Net-Debt Free
2
The company has declared negative results in Jun'2026 after 2 consecutive positive quarters
  • OPERATING CASH FLOW(Y) Lowest at CNY 52.95 MM
  • NET PROFIT(HY) At CNY -17.79 MM has Grown at -37.2%
  • RAW MATERIAL COST(Y) Grown by 17.01% (YoY)
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 54.67%, its profits have risen by 51%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Jiangsu Nanfang Medical Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Jiangsu Nanfang Medical Co., Ltd.
49.02%
2.53
52.41%
China Shanghai Composite
0.9%
0.22
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-12.05%
EBIT Growth (5y)
-191.83%
EBIT to Interest (avg)
-3.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.59
Sales to Capital Employed (avg)
0.74
Tax Ratio
7.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
2.75%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
11.82
EV to EBIT
-30.10
EV to EBITDA
-52.27
EV to Capital Employed
4.34
EV to Sales
4.14
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-14.40%
ROE (Latest)
-57.03%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
NET PROFIT(HY)

Higher at CNY -17.79 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 3.82 times

DEBTORS TURNOVER RATIO(HY)

Highest at 4.67 times

-14What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at CNY 52.95 MM

NET PROFIT(HY)

At CNY -17.79 MM has Grown at -37.2%

RAW MATERIAL COST(Y)

Grown by 17.01% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 244.54 %

NET SALES(Q)

Lowest at CNY 115.76 MM

Here's what is working for Jiangsu Nanfang Medical Co., Ltd.

Net Profit
Higher at CNY -17.79 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Inventory Turnover Ratio
Highest at 3.82 times and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio
Highest at 4.67 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Jiangsu Nanfang Medical Co., Ltd.

Net Sales
At CNY 115.76 MM has Fallen at -20.81%
over average net sales of the previous four periods of CNY 146.17 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Net Profit
At CNY -17.79 MM has Grown at -37.2%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Operating Cash Flow
Lowest at CNY 52.95 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales
Lowest at CNY 115.76 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Debt-Equity Ratio
Highest at 244.54 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 17.01% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading